Literature DB >> 33067680

Intracranial aneurysm management in patients with late-onset Pompe disease (LOPD).

Francesca Granata1, Antonio Toscano2, Enricomaria Mormina3,4, Olimpia Musumeci2, Agostino Tessitore1, Anna Ciranni2, Graziana Tavilla2, Antonio Pitrone1, Sergio Lucio Vinci1, Antonio Armando Caragliano1, Marcello Longo1.   

Abstract

Pompe disease is a rare hereditary metabolic disorder caused by α-glucosidase (GAA) deficiency. The late-onset form of the disease (LOPD) is considered a multisystemic disorder which could involve vascular system with cerebrovascular abnormalities such as intracranial aneurysms or dolichoectasia. Intracranial aneurysm rupture may represent a life-threatening emergency. A possible treatment of unruptured intracranial aneurysms (UIAs) should consider both aneurysm-related (aneurysmal size, shape, localization, numbers and hemodynamic factors) and patient-related risk factors (patient's age and sex, hypertension, smoke exposure). Moreover, UIAs management of LOPD patients needs also to take into account the altered blood vessels integrity and elasticity, whose consistency is likely weakened by the deficient GAA activity as a further potential risk factor. We herein present our approach for of UIAs management in three patients with LOPD. Among them, only one patient with a left saccular UIA of the anterior communicating artery, after careful consideration of risk factors, underwent the endovascular treatment. The other two patients were scheduled for a 1-year follow-up, according to radiological, clinical, and risk evaluation features. Finally, we would like to suggest some general recommendations for UIAs management. In particular, if no risk factors are identified, a cautious yearly follow-up is suggested; otherwise, if risk factors are present, endovascular treatment should be considered.

Entities:  

Keywords:  Cerebrovascular disorders; Endovascular treatment; Glycogen storage disease II; Intracranial aneurysm; Pompe disease

Mesh:

Substances:

Year:  2020        PMID: 33067680     DOI: 10.1007/s10072-020-04819-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  11 in total

1.  Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis.

Authors:  O Musumeci; S Marino; F Granata; R Morabito; L Bonanno; T Brizzi; V Lo Buono; F Corallo; M Longo; A Toscano
Journal:  Eur J Neurol       Date:  2018-11-15       Impact factor: 6.089

2.  Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  B Gregory Thompson; Robert D Brown; Sepideh Amin-Hanjani; Joseph P Broderick; Kevin M Cockroft; E Sander Connolly; Gary R Duckwiler; Catherine C Harris; Virginia J Howard; S Claiborne Clay Johnston; Philip M Meyers; Andrew Molyneux; Christopher S Ogilvy; Andrew J Ringer; James Torner
Journal:  Stroke       Date:  2015-06-18       Impact factor: 7.914

3.  Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

Authors:  Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

4.  Independent risk factors for intracranial aneurysms and their joint effect: a case-control study.

Authors:  Monique H M Vlak; Gabriel J E Rinkel; Paut Greebe; Ale Algra
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

5.  Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney disease.

Authors:  Hiroki Yoshida; Eiji Higashihara; Keisuke Maruyama; Kikuo Nutahara; Toshiaki Nitatori; Isao Miyazaki; Yoshiaki Shiokawa
Journal:  Acta Neurochir (Wien)       Date:  2017-09-07       Impact factor: 2.216

6.  Risk Factors for the Rupture of Bifurcation Intracranial Aneurysms Using CT Angiography.

Authors:  Guang Xian Wang; Dong Zhang; Zhi Ping Wang; Liu Qing Yang; Lei Zhang; Li Wen
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

Review 7.  The impact of Pompe disease on smooth muscle: a review.

Authors:  Angela L McCall; Jeffrey Salemi; Preeti Bhanap; Laura M Strickland; Mai K Elmallah
Journal:  J Smooth Muscle Res       Date:  2018

8.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

9.  Risk factors for ruptured intracranial aneurysms.

Authors:  Guang-Xian Wang; Dong Zhang; Zhi-Ping Wang; Liu-Qing Yang; Hua Yang; Wen Li
Journal:  Indian J Med Res       Date:  2018-01       Impact factor: 2.375

10.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

View more
  2 in total

1.  miR-139-5p Suppresses Proliferation and Angiogenesis of Intracranial Aneurysm via FGB.

Authors:  Tao Jin; Gong Chen; Qingzhu An; Xuanfeng Qin; Yuanyuan Hu; Yan Yan; Jia Hu; Bing Zhou; Bing Leng
Journal:  J Healthc Eng       Date:  2022-04-16       Impact factor: 3.822

2.  Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease).

Authors:  Huiting Zhang; Jun Chen; Yuchang Zhu; Xiaotang Ma; Wangtao Zhong
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.